Trial Profile
Phase I study of Ramucirumab and Irinotecan for metastatic gastric cancer previously treated with Fluoropyrimidine with/without Platinum and Taxane
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Feb 2019
Price :
$35
*
At a glance
- Drugs Irinotecan (Primary) ; Ramucirumab (Primary)
- Indications Adenocarcinoma; Gastric cancer
- Focus Adverse reactions
- Acronyms G-IRIRAM
- 09 Feb 2019 Status changed from active, no longer recruiting to completed.
- 20 Jan 2018 Results (n=6) assessing maximum tolerated dose and recommended dose of ramucirumab plus irinotecan, presented at the 2018 Gastrointestinal Cancers Symposium.
- 17 Jun 2017 Status changed from recruiting to active, no longer recruiting.